Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients (NCT07430683)
Incidence of Cytomegalovirus Infection or Disease Using Valganciclovir Prophylaxis Versus Preemptive Therapy in Intermediate-Risk (R+) Living Donor Kidney Transplant Recipients Receiving Basiliximab-Based Immunosuppression: An Open-Label Clinical Trial (PREVAIL-KT)
🩺 Plain-English Summary (8th-Grade Level)
Cytomegalovirus (CMV) infection remains one of the most frequent infectious complications after kidney transplantation. In intermediate-risk recipients (seropositive, R+ recipient) of living donor kidney transplants, optimal prevention strategies remain debated, particularly in the setting of basiliximab-based induction therapy. This open-label clinical trial aims to compare the incidence of CMV infection or disease in intermediate-risk (R+) living donor kidney transplant recipients receiving valganciclovir prophylaxis versus a preemptive therapy strategy. All patients receive basiliximab-based immunosuppression as part of standard clinical practice. Participants were enrolled between March 1, 2024 and July 31, 2025. Patients are followed for 12 months post-transplantation to assess the primary outcome of CMV infection or disease. Secondary outcomes include graft function, acute rejection episodes, and other infectious complications. The results of this study may help define the optimal CMV prevention strategy in intermediate-risk living donor kidney transplant recipients under basiliximab-based immunosuppression.
Who can join: Review the eligibility criteria below.
Location: Universidad de Guadalajara — Guadalajara, Jalisco
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Universidad de Guadalajara — Guadalajara, Jalisco
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cytomegalovirus Infections
- Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation — Phoenix, Arizona
- Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients — Boston, Massachusetts
- Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients — Houston, Texas
- Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients — Philadelphia, Pennsylvania
- T Cell Therapy of Opportunistic Cytomegalovirus Infection — Cleveland, Ohio
Explore by condition: All Cytomegalovirus Infections clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.